Showing results (41-50 of 55) with videos related to
Sort By:
Pageof 6
Science Bulletin|December 22, 2022
Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective studyLan-Ping Xu, Zheng-Li Xu, Shun-Qing Wang, et al.Haematologica|May 26, 2022
Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based studyZheng-Li Xu, Lan-Ping Xu, De-Pei Wu, et al.Science Bulletin|February 3, 2026
Who is the best allogeneic hematopoietic stem cell transplant donor for severe aplastic anemia? Data from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG)Zheng-Li Xu, Lan-Ping Xu, Shun-Qing Wang, et al.Science China. Life Sciences|February 23, 2020
Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia: a real-world studyYu Wang, Qi-Fa Liu, De-Pei Wu, et al.Journal of Hematology & Oncology|September 4, 2019
Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter studyLan-Ping Xu, Shun-Qing Wang, Yan-Ru Ma, et al.Blood Advances|November 13, 2019
Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopeniaQiu-Sha Huang, Jing-Zhi Wang, Ya-Zhen Qin, et al.Bone Marrow Transplantation|December 2, 2024
Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter studyJie Sun, Yi-Cheng Zhang, Jia Wei, et al.Blood Advances|April 20, 2023
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm studyLi-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, et al.The Oncologist|October 13, 2025
Real-world effectiveness of mitoxantrone hydrochloride liposome containing regimens in acute myeloid leukemiaTie-Jun Gong, Wei-Ming Li, Li Liu, et al.American Journal of Hematology|January 22, 2022
Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysisXiao-Dong Mo, Shen-Da Hong, Yan-Li Zhao, et al.Pageof 6